The role of cyclic AMP, calcium and filamentous actin in adenosine modulation of Fc receptor-mediated phagocytosis in human neutrophils.
The role of cyclic AMP, calcium and filamentous actin (F-actin) content during adenosine modulation of Fc receptor (FcR)-mediated phagocytosis in adherent human neutrophils was investigated. Phagocytosis of IgG-opsonized yeast particles was found to be enhanced by pico- to nanomolar concentrations of adenosine or the A1-agonist N6-cyclopentyl-adenosine (CPA) but reduced by micromolar concentrations of adenosine or the A2-agonist 5'-N-ethylcarboxamidoadenosine (NECA). NECA, in the presence of the cAMP-specific phosphodiesterase inhibitor Ro 20-1724, increased the intracellular content of cAMP during phagocytosis. Ro 20-1724 potentiated the NECA-induced reduction of the phagocytic capacity. These observations indicate that cAMP elevations are involved in A2-receptor-mediated inhibition of phagocytosis. NECA, in the presence of Ro 20-1724, markedly enhanced the action polymerization associated with adhesion to the substrate and contact with the phagocytic prey. During advanced phagocytosis, however, the F-actin content reached levels clearly below those observed in control cells. This prolonged depolymerization phase correlated with the A2-receptor-induced cAMP elevation. Depletion of intracellular free calcium abolished the cAMP-elevating effects of NECA, and also completely abrogated the A1- and A2-receptor-mediated effects on phagocytosis. However, since NECA reduced the F-actin content even in Ca(2+)-depleted cells, A2-receptor-mediated inhibition of phagocytosis could not be directly coupled to changes in the overall content of F-actin. Our results indicate that adenosine modulates FcR-mediated phagocytosis in a calcium-dependent way, and does so through 'stimulatory' A1 and 'inhibitory' A2 receptors, and also that cAMP elevation is linked to the A2-receptor-induced inhibition of phagocytosis.
Department of Medical Microbiology, Faculty of Health Sciences, University of Linköping, Sweden.
S
S
Zalavary
O
O
Stendahl
T
T
Bengtsson
D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000199:Actins / Q000378:metabolism / Q000494:pharmacology*; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D019830:Adenosine-5'-(N-ethylcarboxamide); D002118:Calcium / Q000378:metabolism / Q000494:pharmacology*; D000242:Cyclic AMP / Q000494:pharmacology*; D006801:Humans; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010587:Phagocytosis; D011961:Receptors, Fc / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology*; D018047:Receptors, Purinergic P1 / Q000187:drug effects
D000199:Actins; D011961:Receptors, Fc; D018047:Receptors, Purinergic P1; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D019830:Adenosine-5'-(N-ethylcarboxamide); D000242:Cyclic AMP; D000241:Adenosine; D002118:Calcium